Bordeaux Wealth Advisors LLC Increases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Bordeaux Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 695 shares of the company’s stock after purchasing an additional 88 shares during the quarter. Bordeaux Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $405,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Goldstream Capital Management Ltd increased its stake in Eli Lilly and Company by 190.6% in the 4th quarter. Goldstream Capital Management Ltd now owns 5,685 shares of the company’s stock valued at $3,314,000 after buying an additional 3,729 shares during the period. Montis Financial LLC boosted its holdings in shares of Eli Lilly and Company by 9.4% in the fourth quarter. Montis Financial LLC now owns 464 shares of the company’s stock valued at $271,000 after acquiring an additional 40 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in shares of Eli Lilly and Company by 49.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 8,294 shares of the company’s stock worth $4,834,000 after acquiring an additional 2,746 shares during the period. Aveo Capital Partners LLC increased its stake in shares of Eli Lilly and Company by 8.2% during the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after acquiring an additional 153 shares during the period. Finally, Levin Capital Strategies L.P. raised its holdings in Eli Lilly and Company by 3.8% during the fourth quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock worth $242,000 after purchasing an additional 15 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of LLY stock traded down $20.94 during trading hours on Friday, hitting $734.97. The company’s stock had a trading volume of 4,535,213 shares, compared to its average volume of 3,087,178. The business has a fifty day moving average of $761.75 and a 200-day moving average of $670.56. The stock has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.57 and a beta of 0.37. Eli Lilly and Company has a twelve month low of $419.80 and a twelve month high of $800.78. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.62 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 13.49 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on LLY shares. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Truist Financial lifted their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday. Barclays upped their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, Bank of America upped their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.